Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401668 · ClinicalTrials.gov registry record · NA
Impact of a Community Health Worker Strategy on Produce Prescription Program Uptake Among People With Diabetes
A NA study of Diabetes Type 2, sponsored by Yale University.
- Active
- Registry status
- NA
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT06401668: Active NA study of Diabetes Type 2, sponsored by Yale University.
NCT06401668 is a NA study of Diabetes Type 2 that is active but no longer recruiting, run by Yale University. The registered enrollment target is 116 participants, below the 663-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401668, a NA study of Diabetes Type 2, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
Produce prescription programs (PRx) are promising interventions for improving health outcomes for patients with both type 2 diabetes (T2D) and food insecurity, but uptake has been suboptimal. There is a critical need for scalable, evidence-based implementation strategies for improving PRx uptake and optimizing the effectiveness and cost-effectiveness of these interventions. This study will co-design and pilot a community health worker (CHW) strategy and test the effectiveness of the strategy compared to PRx participants without a CHW. The overall objective of this study is to test and evaluate a theory-informed, user-centered community health worker (CHW) implementation strategy to improve uptake of a PRx, among Hispanic Medicaid-eligible patients with T2D in Connecticut (CT). CHWs will offer participants personalized support by overcoming barriers and leveraging facilitators to PRx uptake.
Primary Outcome
PRx redemption is defined as produce debit card dollars used/total dollars available will be collected from the produce debit card platform.
Conditions Studied
Interventions
- BEHAVIORAL Community health worker (CHW) strategy
- BEHAVIORAL PRx Program
Study Locations (1)
Connecticut
- Hartford HealthCare/ St. Vincent Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT06401668 still lists
NCT06401668 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Community health worker (CHW) strategy is the first listed.
NCT06401668 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06401668 about?
NCT06401668 is a clinical study titled "Impact of a Community Health Worker Strategy on Produce Prescription Program Uptake Among People With Diabetes". Produce prescription programs (PRx) are promising interventions for improving health outcomes for patients with both type 2 diabetes (T2D) and food insecurity, but uptake has been suboptimal. There is a critical need for scalable, evidence-based implementation strategies for improving PRx uptake and...
What is the current status of trial NCT06401668?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 116 participants. The study started on 2025-04-08. Estimated completion is 2026-03-31.
What conditions does trial NCT06401668 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06401668?
The interventions under investigation include: Community health worker (CHW) strategy (BEHAVIORAL), PRx Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06401668?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401668 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06401668's enrollment target sits among peer trials
116 17th of 24 higher than 8 of 24 other Diabetes Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
RECRUITING · NA
-
FELLAShip to Better Health
RECRUITING · NA
-
Healthy Living Anson Study
RECRUITING · NA
-
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI